Illumina , Inc. ( ILMN ) Piper Jaffray Healthcare Conference December 3, 2013 9:00 a.m ..... pleasure to introduce to my right Senior Vice President and CFO of Illumina , Marc Stapley to our 25 th annual conference. And to Marc’s right
Nov 21 (Reuters) - Illumina Inc : * Cowen raises price target to $105 from $90; rating outperform For a summary of rating and price target changes on U
Illumina ( ILMN ) has received approval for four "next-generation" gene-sequencing devices that have the potential to make quicker and more
Illumina ( ILMN -0.7% ) appoints Francis deSouza President. DeSouza, who has an enterprise ..... at Symantec ( SYMC ) and is also Chairman of MedHelp. DeSouza will join ILMN next month. ( PR ) Post your comment!
By EP Vantage : It is beginning to look as if relying on patents covering naturally-occurring molecules might not be a good strategy for diagnostics companies. Following the rug-pull the US Supreme Court delivered to Myriad Genetics ( MYGN ) by disallowing its patents covering breast cancer genes,
acquisition of Gen-Probe, Roche's attempted takeover of Illumina ILMN --could be an impetus for other companies to pursue ..... an EV/EBITDA near or below the implied levels for Illumina and Gen-Probe. While we view the immediate possibility
Illumina ( ILMN -0.7% ) is set to acquire NextBio ..... for research and clinical applications." ILMN says the deal will allow it to "offer customers ..... discoveries within healthcare." ( PR ) ILMN also affirms its 2013 guidance for good
PropThink: By Ivan Deryugin Shares of Illumina ( ILMN ) have risen over 85% since our ..... shares at an all-time high, Illumina should remain a facet of a balanced ..... due to incremental dilution from Illumina 's slate Complete Story »
Illumina ( ILMN ) Q3 2013 Earnings Call October 21, 2013 5:00 pm ET Executives Rebecca ..... a href='http://seekingalpha.com/article/1758772- illumina -management-discusses-q3-2013-results-earnings-call-transcript
Oct 21 (Reuters) - Gene sequencing products maker Illumina Inc's results beat analysts' estimates for the eighth straight quarter, and the company forecast higher-than-expected earnings for the year.